Characterisation of paediatric pulmonary hypertensive vascular disease from the PPHNet Registry.

Competing Interests: Conflict of interest: S.H. Abman has nothing to disclose. Conflict of interest: M.P. Mullen reports grants from the National Heart, Lung, and Blood Institute, during the conduct of the study; personal fees from Actelion, outside the submitted work. Conflict of interest: L.A. Sleeper reports grants from the National Heart, Lung, and Blood Institute (subcontract from University of Colorado), during the conduct of the study. Conflict of interest: E.D. Austin has nothing to disclose. Conflict of interest: E.B. Rosenzweig reports grants from the National Institutes of Health, during the conduct of the study. Conflict of interest: J.P. Kinsella has nothing to disclose. Conflict of interest: The University of Colorado contracts with Actelion, Bayer, Gilead and United Therapeutics for D. Ivy to be a consultant and preform clinical research trials. Conflict of interest: R.K. Hopper has nothing to disclose. Conflict of interest: J.U. Raj has nothing to disclose. Conflict of interest: J. Fineman has nothing to disclose. Conflict of interest: R.L. Keller reports grants from the National Heart, Lung, and Blood Institute, during the conduct of the study. Conflict of interest: A. Bates has nothing to disclose. Conflict of interest: U.S. Krishnan has nothing to disclose. Conflict of interest: C.M. Avitabile has nothing to disclose. Conflict of interest: A. Davidson has nothing to disclose. Conflict of interest: M.D. Natter reports grants from the National Heart, Lung, and Blood Institute, during the conduct of the study. Conflict of interest: K.D. Mandl reports no specific conflicts, however in the interest of full disclosure, reports personal fees from Merck, and philanthropy from Eli Lily to his lab, during the conduct of the study.